September 30, 2024
The University of Cincinnati's LaTrice Montgomery joined WVXU's Cincinnati Edition to discuss youth drug prevention programs and what research says about the most effective approaches.
September 30, 2024
University of Cincinnati Cancer Center experts present research at the American Society for Radiation Oncology (ASTRO) Annual Meeting Sept. 29 through Oct. 2.
October 4, 2024
The University of Cincinnati’s Debanjan Bhattacharya is first author of new research published in Cancers that found the drug AM-101 improves the effectiveness and survival rate of radiation treatment in animal models of lung cancer that has spread to the brain.
October 4, 2024
The University of Cincinnati's Pooja Khatri was featured in an MSN and Huffington Post UK article discussing how symptoms of stroke can look different for women.
October 7, 2024
Medscape highlighted new research from the University of Cincinnati and Cincinnati Children's Hospital's Donald Gilbert that found a new drug reduces tic severity in children and adolescents with Tourette syndrome without exacerbating common psychiatric comorbidities.
October 8, 2024
The University of Cincinnati's Russell Sawyer was featured in a Lake Charles, Louisiana television station KPLC story defining the differences between frontotemporal and alcohol-induced dementia.
October 9, 2024
Lake Charles, Louisiana television station KPLC highlighted the story of Air Force veteran Tyler Nuttle, who received a second opinion and underwent a successful surgery to remove a brain tumor at the University of Cincinnati.
October 14, 2024
The University of Cincinnati Blue Ash College's Krysten Stein spoke with CNN about the complicated motivations behind online influencers creating content in unsafe evacuation zones during recent hurricanes.
October 16, 2024
The University of Cincinnati's Melinda Butsch Kovacic was featured in a WCPO story highlighting the first-ever Hamilton County State of Cancer forum and health expo.
October 18, 2024
The University of Cincinnati’s Brandon Foreman, MD, presented Phase 3 clinical trial results at the Neurocritical Care Society’s 22nd Annual Meeting this week in San Diego, California that found ganaxolone is a safe and effective treatment for refractory status epilepticus.